XERS News and Press, Xeris Pharmaceuticals Inc. From 08/08/23

2023-08-08 07:06:57 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q2 GAAP EPS of -$0.14 misses by $0.01 . Revenue of $38.01M (+50.2% Y/Y) beats by $3.17M . “We posted another record quarter of revenue due to the continued strong demand of all ...

Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens full-year 2023 guidance: total net revenue of $145M-$165M; cash utiliz...

2023-08-07 13:39:24 ET Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $34.84M (+37.7% Y/Y). Over the last 2 years...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...

U pdated guidelines recognize the benefits of ready-to-use glucagon Protecting all people with diabetes at risk of severe hypoglycemia remains the goal Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients&...

--News Direct-- Xeris Biopharma CEO Paul Edick joined Proactive's Natalie Stoberman to share the resignation of the company's Chief Scientific Officer and Founder Dr. Steven Prestrelski as he transitions to a consulting role with Xeris. Edick said the impact of Dr. Prestrelski steppin...

--News Direct-- Xeris Biopharma Chairman & CEO Paul Edick joins Natalie Stoberman from the Proactive newsroom to share the latest milestone of having its first participant being dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidi...

Novel formulation of levothyroxine sodium (SC injection) to potentially mitigate many of the challenges associated with oral formulations of levothyroxine. Phase 2 study to establish the average once-weekly dose, accrue additional safety data, and facilitate a future Phase 3 program ...

--News Direct-- Xeris Pharmaceuticals chairman and CEO Paul Edick joins Natalie Stoberman from the Proactive studios to discuss the latest updates on product line performance. Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by develop...

2023-06-16 20:41:21 ET Summary Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, such as Glucagon and Gvoke, and is aggressively sec...